|
Video: What is a Stock Split?
|
|
Janux Therapeutics is a biopharmaceutical company engaged in the development of a pipeline of immunotherapies by applying Co.'s proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and TRACIr platforms to treat patients suffering from cancer. Co.'s initial focus is on developing a class of T cell engagers, and Co.'s primary product candidates are designed to target clinically validated drug targets. Co. is developing a pipeline with programs targeting prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2, with all of Co.'s programs in the preclinical or discovery stage. According to our Janux Therapeutics stock split history records, Janux Therapeutics has had 0 splits. | |
|
Janux Therapeutics (JANX) has 0 splits in our Janux Therapeutics stock split history database.
Looking at the Janux Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Janux Therapeutics shares, starting with a $10,000 purchase of JANX, presented on a split-history-adjusted basis factoring in the complete Janux Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/14/2021 |
|
End date: |
05/03/2024 |
|
Start price/share: |
$20.16 |
|
End price/share: |
$64.78 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
221.33% |
|
Average Annual Total Return: |
49.82% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$32,135.71 |
|
Years: |
2.89 |
|
|
|
|
|